Effects of TA-3090, a new calcium channel blocker, on myocardial substrate utilization in ischemic and nonischemic isolated working fatty acid-perfused rat hearts.
Population
Isolated working rat hearts perfused at 11.5 mm Hg preload and 80 mm Hg afterload with Krebs-Henseleit…
Comparison
TA-3090 added to the perfusate before ischemia… vs Control conditions
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
TA-3090 pretreatment may preserve energetics in ischemic rat hearts; leaves open translation to human cardioprotection.
Structured PICO
P
Population
Isolated working rat hearts perfused at 11.5 mm Hg preload and 80 mm Hg afterload with Krebs-Henseleit buffer containing 11 mM glucose, 1.2 mM palmitate, and 500 microunits/ml insulin
I
Intervention
TA-3090 (0.5 microM) added to the perfusate before ischemia or at the time of reperfusion
C
Comparator
Control conditions (aerobic perfusion without TA-3090, or TA-3090 added at reperfusion instead of before ischemia)
O
Outcome
Myocardial substrate utilization (fatty acid and glucose oxidation, glycolysis) and reperfusion recovery of mechanical functionsurrogate
In an isolated rat heart model, the calcium channel blocker TA-3090 improved reperfusion recovery and preserved ATP when administered prior to ischemia, likely by decreasing myocardial energy demand and glycolysis during ischemia.
Cite This Study
Davies et al. (1991) studied this question.